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In this review, we discuss insights gained through the use of stem cell preparations
regarding the modeling of neurological diseases, the need for aging neurons derived
from pluripotent stem cells to further advance the study of late-onset adult neurological
diseases, and the extent to which mechanisms linked to the mismanagement of reactive
oxygen species (ROS). The context of these issues can be revealed using the three disease
states of Parkinson’s (PD), Alzheimer’s (AD), and schizophrenia, as considerable insights
have been gained into these conditions through the use of stem cells in terms of disease
etiologies and the role of oxidative stress. The latter subject is a primary area of interest
of our group. After discussing the molecular models of accelerated aging, we highlight the
role of ROS for the three diseases explored here. Importantly, we do not seek to provide
an extensive account of all genetic mutations for each of the three disorders discussed in
this review, but we aim instead to provide a conceptual framework that could maximize the
gains from merging the approaches of stem cell microsystems and the study of oxidative
stress in disease in order to optimize therapeutics and determine new molecular targets
against oxidative stress that spare stem cell proliferation and development.
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INTRODUCTION
In central nervous system (CNS) neurons, certain characteristic
changes serve as cues for the advanced maturational state of
both the cell and the organism. These include altered calcium
metabolism, changes in cell energy metabolism secondary to
altered cerebral blood flow, increased mitochondrial (mt) content
and reduced oxidative metabolism (Stoll et al., 2011). In fact,
at the cellular level, many age-related impairments ultimately
converge to negatively impact cell respiration, which manifests
as the overproduction of reactive oxygen species (ROS). It is for
this reason that the roles of ROS in age-related change and in
the exacerbation of age-related neurological diseases will be a
primary focus of this review, although other indicators of cellular
aging will also be mentioned. Considerable evidence exists to
argue that the age-related overproduction of ROS is associated
with either imbalances of cellular metabolism and the induc-
tion of apoptotic signaling pathway(s) that lead to cell death.
One central objective of the current review is to explore and
highlight specific relationships between metabolic and related
molecular aspects of adult-onset neurological disorders, and the
specific contributions of ROS overproduction to cellular damage
of central neurons that cause the characteristic symptoms of these
diseases.
DIFFERENTIATION AND MATURATION OF PLURIPOTENT STEM CELLS
The introduction of techniques that produce induced pluripo-
tent stem cells (iPSCs) was made by Yamanaka’s group in 2006,
reportedly in response to difficulties in securing approval for
work with human embryonic cells (Takahashi and Yamanaka,
2006). Their methods use human epithelial cells that are
exposed to a series of characterized transcription factors under
highly controlled experimental conditions. The end result
is the production of a population of pluripotent cultured
cells.
One important consideration regarding the use of stem cells
for the investigation of adult-onset neuropathology is that cells
after reprogramming events are restored to an embryonic state
that renders them biochemically and functionally immature. This
molecular and morphological immaturity also translates directly
into a relatively heightened state of adaptive functional plasticity
that could confer resilience to an experimental disease-onset state.
Specific “youth-like” adaptive changes that are seen in iPSCs
converted from fibroblasts are as follows: differentiation rates
reminiscent of fetal cells (Mariani et al., 2012; Nicholas et al.,
2014); upregulation of telomerase activity and elongation of
telomeres (Marion et al., 2009); embryonic mt status with low
levels of adenosine triphosphate (ATP; Suhr et al., 2010); reduced
levels of mtDNA (Kelly et al., 2013); and increased mt membrane
potential (Armstrong et al., 2010).
Many studies have been designed to develop new differentia-
tion protocols, with the specific aim of producing different types
of neurons in vitro. However, most of these protocols require long
time periods to attain specific neuronal subtypes and frequently
result in a low rate of cells with functional properties (Yan et al.,
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2005; Hu and Zhang, 2009). This issue has motivated researchers
to overcome the expense and improbability of generating authen-
tically chronologically “old” cells.
iPSCs became an interesting tool to model disorders as they
retain genetic alterations from the donor. After being repro-
grammed, these cells are usually differentiated into the desired
cell type and can demonstrate a disease-related phenotype when
compared to controls. However, as cells that are generated
by most other differentiation protocols correspond to earlier
developmental stages, recapping specific phenotypes that are
developed by the patient becomes more difficult, especially in
cases of late-onset disorders. In this review, we discuss some
of the strategies that have been and are being developed in
order to overcome this issue. We then describe some age-
related phenotypes that are observed in late-onset disorders,
which can be explored using this new strategy of patient-specific
iPSCs.
ACCELERATED AGING OF NEURONS
Stem cell research into adult disorders has been unlikely to
flourish unless researchers could compress the developmental
timeline. In order to reduce the extension of differentiation
protocols and generate more homogeneous neuronal cells with
robust synapse formation capabilities, Zhang et al. (2013) suc-
cessfully forced the expression of a single transcription factor,
neurogenin, in pluripotent stem cells; they were able to reach
yields and purity levels of almost 100% within 2 weeks (Zhang
et al., 2013). This strategy followed the same rationale that was
used to induce cell reprogramming, resetting an entire biolog-
ical system by inducing the overexpression of a few transcrip-
tion factors. However, it remains unclear whether this approach
prompts the cells to achieve an equivalent chronological age
as those that are present in vivo in patients with age-related
disorders.
In 2009, Saha and Jaenisch proposed that modeling long-latent
disorders would be a challenge for the use of patient-iPSCs as the
dynamics of disease progression in the patient was likely to be
vastly different from any phenotype developed in vitro (Saha and
Jaenisch, 2009). One suggestion made to overcome this issue was
to accelerate the appearance of pathological phenotypes in vitro
by exposing cells to environmental effects that may contribute to
disease pathogenesis, such as oxidative stress.
In 2013, a major and possibly foremost advance in stem cell
technology essentially accomplished this task with the ground-
breaking development by the group of Lorenz Studer (Miller
et al., 2013). They began their study with reconfirmed discrepan-
cies in the molecular phenotypes between organically aged cells
and corresponding iPSC pathway activities. Cells evaluated from
elderly donors had age-related nucleic changes, protein loss, chro-
matin marker changes, and increased numbers of DNA mutations
(Miller et al., 2013). Mitochondrial superoxide levels were also
elevated compared with fibroblasts from younger counterparts,
which incidentally reaffirmed the role of ROS mismanagement as
both a potential cause and indicator of neural disorders. However,
when these “aged” fibroblasts were used to generate iPSCs and
subsequently differentiated, the resulting fibroblasts no longer
showed the molecular signatures of being “aged” but more closely
resembled the molecular status of cells developed from younger
patients (Miller et al., 2013).
Recognizing the importance of an aged cellular state to the
study of adult-onset diseases, these investigators isolated the
genetic basis or underlying mechanism that compressed the
physiological duration of aging cells. They developed a similar
in vitro state as occurs for individuals with Hutchinson-Gilford
progeria syndrome (HGPS). The central damaging mutation
in this disorder is a lack of a cleavage site that leads to the
accumulation of prelamin A in the nucleus and the conse-
quent generation of progeroid syndromes (Smith et al., 2005).
When this mutation was used in isolation at the experimen-
tal level, cells that carried the gene for accelerated aging and
cells from phenotypic donors (both young and old donor cat-
egories) were compared for differences in cellular development
via single cell indicators of physiological or molecular matu-
rity. They discovered that carrying a mutation in lamin A
(LMNA) was associated with the expression of molecular mark-
ers for premature aging. Miller et al. then developed an in
vitro preparation that was useful for measuring the extent to
which the transient expression of progerin was associated with
this “aged” molecular profile. It was found that 3 days of
progerin overexpression yields gene sets that are similar to that
of accelerated aging for either young or old iPSC-derived fibrob-
lasts. The following complement of aging-associated markers
was observed: increased mt dysfunction, DNA damage, nuclear
abnormalities, loss of heterochromatin, and reduced telomere
length. Remarkably, they were able to identify degenerative phe-
notypes that related to PD after mimicking some aspects of
normal aging in neurons, which demonstrated the utility of
their approach for modeling late-onset disorders (Miller et al.,
2013).
Controversially, cognitive functions are preserved in progeroid
syndromes, which might be because LMNA is absent from the
nuclear neural lamina (Jung et al., 2012). Recently, using iPSCs
derived from patients with HGPS, Nissan et al. (2012) confirmed
that the expression of a specific RNA commonly involved in
neural development, miR-9, by neural cells potentially decreases
the expression of LMNA (Nissan et al., 2012). The authors
speculated that these findings could be related to the absence
of cognitive impairments in children affected by progeria after
neural cells lose progerin expression. Therefore, despite the over-
expression of progerin triggering an aged-like state in neural
cells derived from reprogrammed cells, it is not clear whether
this pathway resembles the neural natural aging process. Conse-
quently, it remains to be determined if the acquired phenotypes
are enough to model other neurological late-onset disorders and
whether they actually mimic the aging process in the nervous
system.
CANDIDATE PATHWAYS TO ACCELERATE AGING IN NEURAL CELLS
Developing physiologically complete models of accelerating neu-
ronal aging may require the reconsideration of maturity and
senescence being different events. The origins of neuronal
senescence may belong outside the neuron, and possibly out-
side the brain. Unlike maturity, cellular senescence is repre-
sented by a stage where cells are stably arrested and also
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exhibit phenotypic changes (Rodier and Campisi, 2011). The
global contributors to neuronal aging could also prompt home-
ostatic imbalances that influence repair mechanisms beyond
recoverable limits, therefore initiating or exacerbating CNS
diseases.
Insights from the aged brain
Searching for candidate genes that have the ability to propel
neural development appears to be a reasonable approach, espe-
cially for studies of aging in this cell type. Neural cells are
usually post-mitotic or quiescent, which means that they are
not cycling frequently (Yoshikawa, 2000). As a result, the pro-
cess of senescence does not necessarily follow the same rules
and pathways as actively mitotic cells. The aging process in the
brain is usually accompanied by an increase in the expression
of p16INK4a and a decrease in levels of FGF-2, VEGF, and IGF-1
(Shetty et al., 2005; Molofsky et al., 2006). There is also an aging-
related decline in metabolic function and an increase in oxidative
damage, which is followed by a reduction in the antioxidant
capacity of the brain (Calabrese et al., 2007; Currais and Maher,
2013). In addition, other factors, such as epigenetic regulation
and telomere erosion, are also related to the aging process, which
contribute to the multifactorial nature of neuronal aging. The
specific nature of how these factors contribute to the aging process
has been reviewed elsewhere (Rafalski and Brunet, 2011; Yin
et al., 2013) and not all of these aspects will be explored in this
review.
Once acknowledged as a multifactorial event, it is a challenge
to model the entire cellular aging process in vitro. However, as
the overexpression of progerin can induce certain age-related
phenotypes (Miller et al., 2013), it is reasonable to hypothe-
size that mimicking just one or several factors related to aging
in neural cells would induce similar changes in neural cells.
However, it is important to define whether these changes would
be satisfactory to reproduce a specific phenotype related to
late-onset disease. An alternative approach to reach this aim
would be to find specific transcription factors or other regulators
that could accelerate the aging process by influencing differ-
ent parameters, such as epigenetic parameters and metabolic
status, to produce the opposite effects of the reprogramming
process.
Insights from other systems
Reactive oxygen species. ROS are oxygen-based radicals pro-
duced in most forms of eukaryotic cells through the activi-
ties of enzymes involved in the mt electron transport chain,
cytochrome P450 activities, lipoxygenase or cyclooxygenase,
NAD(P)H oxidases or uncoupled nitric oxide synthase (NOS),
and peroxidases, amongst others (Nayernia et al., 2014). They
are normal by-products of healthy cellular metabolic processes
and are known to play physiologically useful roles in cell sig-
naling; for example, as part of the immunity-oriented “oxida-
tive burst” (Yang et al., 2013a). When cells, including neurons,
are in a homeostatic balance, the availability of enzymes and
scavenging molecules approximately matches local ROS pro-
duction, preventing ROS accumulation and avoiding of cellu-
lar damage (Circu and Aw, 2010). The accumulation of ROS
has been described as a potentially damaging by-product of
aging and ischemia, inflammation, and neuropathology-related
toxicities (Uttara et al., 2009; Liochev, 2013; Chaudhari et al.,
2014).
Viteri et al. (2010) revealed using the HGPS model that oxida-
tive abnormalities in fibroblasts play a large role in premature
aging and that the nature of these changes were consistent with
the normative patterns of cellular aging. More specifically, age-
related increases in H2O2 production reduces FACE1 expression
and thereby impacts levels of prelamin A (Ragnauth et al., 2010).
The findings of Viteri et al. (2010) of typical changes of accel-
erated aging in progeroid models reaffirms the importance of
understanding how ROS is implicated in cellular aging. In fact,
the inappropriate management of the cellular redox status is a
core theme in many theories that explain adult CNS aging and
neuropathology (for review see: Hsieh and Yang, 2013; Kulak
et al., 2013). The concept that ROS accumulation can be a major
precipitating event in CNS pathology has been presented in many
articles and reviews (Nunomura et al., 2001; Dias et al., 2013;
Popa-Wagner et al., 2013). Moreover, unchecked, elevated levels
of ROS eventually impair and oxidize DNA, proteins, lipids,
and/or sugars, which creates cellular dysfunction that leads to
apoptotic and non-apoptotic forms of cell death (Popa-Wagner
et al., 2013).
On the other hand, Le Belle et al. demonstrated in 2011 that
ROS levels were maintained in stem cells at relatively elevated
levels compared with expected values from adult neural tissues;
moreover, they argued that high levels of ROS were central to
maintaining the proliferative state of these neural stem cells (Le
Belle et al., 2011). The beneficial roles of high levels of ROS
for this form of neurogenesis involve the phosphatidylinositol
3-kinase (PI3K)/Akt signaling cascade. Correspondingly, exper-
imental reductions in cellular ROS levels have been associated
with reduced rates of cell growth and proliferation for neural
progenitor cells. Interestingly, their findings were generalized
across both in vitro and in vivo conditions. Such a scenario
may call for further investigation of the specific range of ROS
that induces cell damage or the maintenance of cell culture
conditions for neural progenitors and neurons with accelerated
aging.
Adenosine. In the brain, adenosine forms part of a series of
reactions that provide free energy for neuronal function; how-
ever, adenosine alone also serves as both a neurotransmitter and
neuromodulator (Boison, 2008). Adenosine signaling is mediated
through at least two adenosine receptors: A1 and A2a. The ear-
liest indications that adenosine signaling may influence aspects
of cellular aging and potentially initiate senescence came from
investigations into cancer research and lymphocytes (Parish et al.,
2013; Yang et al., 2013b). While there remains a void in the
neuroscience literature regarding the candidacy of adenosine as
an aging factor in neurons, certain animal studies support its
inclusion in the current list of factors that are noteworthy of
further consideration. For example, adenosine receptors in mouse
increase in an age-dependent fashion, which suggests adeno-
sine may be involved in the aging mammalian brain in general
(Castillo et al., 2009).
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Changes in enzymatic metabolism that occur with age appear
to be a central event underlying adenosine imbalance, if not the
most important factor. Aged rat neurons and human fibroblasts
have been shown to exhibit significantly increased adenosine
kinase activity (Liu et al., 1986; Mackiewicz et al., 2006) and
decreases in adenosine deaminase levels (Ghneim et al., 2003).
Additionally, ATP levels measured in cultures of aged fibrob-
lasts are lower than equivalent values measured in samples of
young fibroblasts (Miyoshi et al., 2006). Finally, aged samples
are more prone to hydrogen peroxide-induced cell damage and
a decline in mt function (Miyoshi et al., 2006). Taken together,
this evidence is useful to suggest that adenosine accumulates
in increasingly old brains due to modifications in enzymatic
complexes that monitor and regulate energetic or redox states.
That much of the work referenced in this section was suc-
cessfully carried out in aged fibroblasts is suggestive of the
suitability of cultures of age-accelerated neurons to determine
how this signaling cascade accounts for physiological correlates
of aging in CNS-specific neurons. More importantly, the par-
ticular combination of altered adenosine signaling and aged
neurons upon a backdrop of a neurological disorder (such as
neurons transformed from patients with schizophrenia) would
become a powerful tool to discover which factors trigger these
disorders.
ADDITIONAL CHALLENGES TO THE SYSTEM
According to a second category of postulates regarding the bio-
logical causes of aging, the original sources of neuronal senes-
cence could reside extraneuronally and potentially even outside
the brain (Rodier and Campisi, 2011). To a large extent, reca-
pitulations of the aging process in iPSCs have not emulated
or addressed these potential triggers. Developing physiologically
complete models of accelerated neuronal aging may require the
reconsideration of this issue and the development of protocols
that can emulate more global or organism-wide conditions of
aging. Specifically, it is known that the aging brain is increas-
ingly poorly served by age-related changes in oxygen or nutri-
ent absorption, ion gradients, or facilitated ion transport, all of
which depend on the integrity and health of cell membranes and
transcriptional states. A practical example of the influences that
circulating substances exert on the prevention of brain aging are
recent studies that showed parabiosis connecting young and old
mice. When the circulatory systems of young and old mice are
connected, it is possible to observe reversion of some age-related
aspects in the brains of the old mice (Katsimpardi et al., 2014;
Villeda et al., 2014). Furthermore, the systemic administration of
blood plasma samples from young mice into aged mice improved
age-related cognitive impairments in terms of both contextual
fear conditioning and spatial learning and memory (Villeda et al.,
2014).
It is also important to consider that in vivo, local sources of
ROS and biochemical cues of aging stem from both neuronal
and non-neuronal sources. For example, it is known that LMNA
production results from the processing of prelamin A by the
removal of the farnesyl residue by FACE1, a metalloproteinase, in
both neuronal and non-neuronal CNS cells (Liu and Zhou, 2008).
Defects in this metalloproteinase such as the lack of a key cleavage
site (as in case of progerin) leads to the accumulation of prelamin
A in vascular smooth muscle (Ragnauth et al., 2010), which
is important for controlling or “matching” blood flow to neu-
ronal demand. Functional mismatches in delivery and neuronal
metabolic demand may be further exaggerated by the increased
rigidity and frailties of the aging cerebral vascular system, and
thereby constitutes a source of oxidative stress (Ragnauth et al.,
2010). Finally, another form of change coincident with truncated
LMNA is compromise of the blood brain barrier, which could
further exaggerate pre-existing biochemical vulnerabilities and/or
the extracellular accumulations of ROS and consequent cellular
damage.
Moreover, it is also known that chronic inflammation is
associated with normal aging and age-related pathophysiologic
processes and diseases, including AD, schizophrenia, and cancer,
among others (Wyss-Coray, 2006; Federico et al., 2007; Saetre
et al., 2007). The inflammatory process is frequently accompa-
nied by the generation of free radicals and mediators, such as
chemokines and cytokines, which converge on the production of
reactive species (Federico et al., 2007). The “senescence-associated
secretory phenotype” (SASP), which includes growth factors,
proteases, chemokines, and cytokines, are usually induced by
cellular senescence and act in an autocrine feedback loop to
reinforce the senescence growth arrest and recruit components of
the immune system to clear senescent cells. The first manifestation
of senescence is the expression of IL-1α, a cytokine that binds to
the IL-1 receptor to initiate the transcription of factors such as
NF-κB and C/EBPβ. These transcription factors are responsible
for triggering many SASP proteins, including IL-6, IL-8 and IL-
1α, which intensify the SASP in a positive feedback manner.
Although some SASP proteins recruit immune cells to eliminate
senescent cells, others can escape from this clearance and express
SASP proteins in a chronic manner to continue the inflammatory
scenario and drive aging (for review see Rodier and Campisi,
2011). While many pathways mentioned in this review touch
upon mechanisms that are common to neuronal failures as a
result of elevated ROS and the mechanisms that play in age-
related complications mentioned here, little is known about their
specific relationships or how best to model such relationships
experimentally. The age-related aspects that really should be reca-
pitulated to provide tools for the modeling of late-onset diseases
remain to be determined.
MODELING DISEASES WITH iPSCS
Pathology in the CNS or “central” pathologies that are present
from birth are often associated with clear and strong trends of
heritability or specific in utero experiences. However, when the
clinical onset of pathology occurs beyond the second decade
of life, as frequently observed in PD, AD, and schizophrenia,
tracing the underlying cellular mechanisms becomes even more
complex. We decided to focus our discussion on these three
pathologies due to the considerable insights gained through the
use of stem cells with respect to both disease etiologies and the
roles of oxidative stress, with the latter subject being a primary
area of interest in our research group. Furthermore, all of these
disorders share age-related phenotypes that are implicated in
impaired levels of cognition. This suggests that the approach that
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FIGURE 1 | Adapted from, “ROS and Brain Disease: the Good, Bad and
the Ugly” Popa-Wagner et al., 2013. This schematic shows the
relationship between pathology-induced neuronal damage and ROS
accumulation on overt clinical symptoms.
propels neuronal aging in vitro will be particularly important for
the modeling these disorders to enable the identification of age-
related phenotypes, as it has already been shown for PD (Miller
et al., 2013).
In this section, we have focused on ROS as the central player
in the pathogenesis of these diseases as many age-related impair-
ments ultimately converge on and negatively impact cell respira-
tion, resulting in the overproduction of ROS.
A SPECIAL CONSIDERATION OF ROS
Due to recent advances in stem cell technology that now allow for
the development of aged neurons to be integrated with genetic
backdrops of adult neurological disease, we are uniquely posi-
tioned to conduct the de novo exploration of molecular networks
that are common to aging, in addition to the co-existing patholog-
ical and redox states, such that new candidate targets may emerge
that can harness oxidative stress and slow disease progression.
As mentioned before, besides being related to the aging pro-
cess, ROS are also closely associated with the pathogenesis of
several diseases, including AD, PD, and schizophrenia (Barnham
et al., 2004; Uttara et al., 2009; Paulsen et al., 2012). Figure 1
provides an example of how the symptoms of oxidative stress
and metabolic mismanagement may manifest upon the back-
drop of disease and explains the alignment of these symptoms
within known pathologies for prominent age-related neurological
disorders.
In this review, we interpret this form of disease modeling as
one that captures the cycle of damage whereby the inherited disor-
der leads to cell damage and local elevations in ROS. In Figure 2,
we have summarized what we understand to be key considerations
in adult neurological disorders that would generate this type of
positive feedback on ROS generation and ultimately generate a
spiral of neurons towards cell death.
FIGURE 2 | Flow chart that represents the positive feedback model of
ROS-related neuropathology in adults. In this postulate, genetically
inherited susceptibilities alone or those compounded by dietary
inadequacies trigger the accumulation of ROS. Upon surpassing the redox
capacity of the cell during the second phase of the cell cycle, ROS-related
damage occurs and invokes death-signaling cascades. Positive feedback is
complete when the biological capacity for redox management continues to
fail to meet cellular needs and fails to adequately combat oxidative stress.
Future studies regarding ROS in iPSC systems of neuropathology that aim
to elucidate mechanisms of AD and PD may be facilitated by coupling the
genetic background of accelerated aging with clinical factors in patients and
carriers of early adulthood forms of neurological disease.
ROS in the interplay of neurodegenerative diseases
Mitochondrial dysfunction and oxidative stress operate together
to produce the normal aging phenomenon. Therefore, it is unsur-
prising that these mechanisms could play important roles in the
development of late-onset neurodegenerative diseases. Alterations
in the redox system occur via genetic or non-genetic factors,
which results in increased levels of ROS in most cases that trigger
oxidative damage within the neural system. Here, we discuss
some of the evidence that places ROS as a key molecule for late-
onset neurodegenerative diseases. However, whether this event
represents the cause or consequence of pathogenic processes
is the focus of controversy. The major molecular alterations
that occur in PD, AD, and schizophrenia are summarized in
Table 1.
Parkinson’s disease. PD is the second most common neurode-
generative disorder and most frequently affects elderly individ-
uals. During the course of the pathogenesis of PD, the loss
of dopaminergic neurons from the substantia nigra results in
movement and postural dysfunction. With disease progression,
neuronal loss spreads to other brain regions and symptoms
such as hallucinations and dementia can emerge. Sporadic and
familial cases share genetic components, although the etiology is
unknown in most cases (For review see Bertram and Tanzi, 2005;
Badger et al., 2014). Interestingly, oxidative stress appears as a
common feature in patients. Reduced activity levels of complex
I of the mt electron-transport chain have been described in
patients with PD (Keeney et al., 2006). Furthermore, the selec-
tive inhibition of this complex by specific compounds such as
rotenone can induce a parkinsonian phenotype (Cannon et al.,
2009).
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Table 1 | Summary of molecular cascades and involvement
categorized by disorder.
Disorder Molecular changes Age-related
affecting redox capacity ROS imbalances
Parkinson’s
disease
Parkin mutations, acts
on β-catenin degrada-
tion
L-type Ca2+ channels in
dopamine neurons increase
intracellular calcium creating
a metabolic stress with
production of ROS
α-Synuclein mutations,
impairs proteasome-
mediated proteolysis
Impaired mitochondrial
complex I activity
PINK deficiency causes mito-
chondrial Ca2+ accumulation
with stimulation of ROS pro-
duction
Reduced GSH activity
LRRK2 mutations
(encodes the Ras/Rho-
like GTPase domain)
Alzheimer’s
disease
Reduction in reelin Disruption in calcium homeost-
asis associated with increased
ROS accumulation and dam-
age
Reduced Akt levels in
Th neurons
Accumulation of reelin p53 conformational alterations
due to oxidative stress
Aberrant GSK3β
Schizophrenia EPHB1 mutations, acts
on GTPase (Ras/Rho)
Age-related reductions in Wnt
signaling
AKT-1, upregulated in
oxidative stress
Increased ROS and extra mito-
chondrial O2 consumption
Reduction in reelin
Reduced GSH activity
Impaired mitochondrial
complex I activity
The genes that are most frequently associated with the pathol-
ogy of PD are α-sinuclein (SNCA), leucine rich repeat kinase
2 (LRRK2), glucocerebrosidase (GBA), PTEN induced kinase
1 (PINK1), parkin (PARK2), and DJ (PARK7) (Badger et al.,
2014). PINK1 and parkin function together, whereby PINK1
accumulates in the mt and parkin depolarizes the mt membrane
to promote the autophagy of damaged mitochondria. Mutations
in any of these genes lead to impaired functionality of the others,
with consequent changes in mt metabolism. Dopaminergic neu-
rons derived from iPSCs with PINK mutations are vulnerable to
oxidative stress once the depolarization of mt membrane reduces
the levels of glutathione synthase (GSH) and, as a consequence,
increases ROS levels (Cooper et al., 2012). Mutations in LRRK2 of
iPSCs-derived neurons leads to the accumulation of α-synuclein,
the increased expression of oxidative stress genes, and vulner-
ability to hydrogen peroxide (Nguyen et al., 2011). Although
the SNCA protein does not have a clear role in the pathology
of PD, its accumulation leads to increased neuronal death due
to their greater vulnerability to oxidative stress (Byers et al.,
2011).
Alzheimer’s disease. As the most prevalent neurodegenerative
disorder in elderly people, AD is characterized by the progres-
sive loss of memory and cognitive decline (Bertram and Tanzi,
2005). The increase in life expectancy predicts that the preva-
lence of this disorder will rise considerably in future decades.
The deposition of amyloid-β (Aβ) derived from the cleavage of
amyloid precursor protein (APP) by β and γ-secretases and the
hyperphosphorylation of Tau (a microtubule-associated protein)
are the hallmarks of AD (Bertram and Tanzi, 2005; Jin et al.,
2011). Oxidative damage occurs during the initial stage of AD
(Nunomura et al., 2001) and leads to Aβ deposition and Tau phos-
phorylation (Melov et al., 2007). Moreover, superoxide dismutase
(SOD) deficiency mice exhibit accelerated Aβ oligomerization
(Murakami et al., 2011) and the hyperphosphorylation of Tau
(Melov et al., 2007).
In addition to the well-described events that occur during the
progression of AD, other molecular alterations also appear to be
connected to the pathology. Patients with AD can exhibit the
accumulation of reelin (Botella-López et al., 2006). The reelin
protein is known to be involved with the organization of the
developing CNS, whereas it has been implicated in signaling path-
ways implicated in neurodegeneration in the adult brain. During
periods of elevated membrane potential, reelin typically interacts
with the apolipoprotein E (ApoE) receptor to increase levels of
intracellular calcium via the NMDA receptor (Herz and Chen,
2006). Therefore, changes in reelin signaling could potentially
drive a mismatch between physiologically appropriate levels of
calcium and the parallel activation of other cascades involved
in neuronal excitation and the redox state (Bezprozvanny and
Mattson, 2008).
In addition, a further two molecules have been also linked
to the pathogenesis of AD: Akt and GSK3β. Akt regulates the
functionality of GSK3β by inducing its phosphorylation, with the
consequent inactivation of GSK. The so-called GSK3β hypothesis
of AD has been explored (reviewed by Hooper et al., 2008) and the
molecule is thought to be linked to the hyperphosphorylation of
Tau and increased deposition of Aβ. Patients with AD frequently
exhibit reduced levels of Akt (Ryder et al., 2004), which in turn
increases the activity of GSK3β.
Schizophrenia. Schizophrenia is considered to be a heteroge-
neous chronic illness with a combined genetic background and
environmental influences; the latter plays a fundamental role once
the disorder occurs. In identical twins, schizophrenia develops
in both twins in almost 50% of cases (Cardno and Gottesman,
2000). Defined as a neural connectivity disorder with regional
synaptic deficits and abnormal synaptic pruning, it is believed to
be a neurodevelopmental disorder that is commonly diagnosed
in adolescence (Murray and Lewis, 1987; Insel, 2010). Apart
from genetic changes, one biochemical factor that appears to be
common between patients with schizophrenia is the increased
levels of ROS that can impact many processes, including those
in neurons. One hypothesis is that the largest source of ROS
comes from complex 1 of the mt electron transport chain. It is
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 292 | 6
Campos et al. Accelerating neuronal development and disease
interesting to note that platelets of patients with schizophrenia
presents with higher complex 1 activity levels compared to healthy
control individuals (Dror et al., 2002), which indicates that
ROS production levels in patients with schizophrenia are high.
Moreover, there are many other genetic and environmental risk
factors for the development of schizophrenia that are known
to induce oxidative stress (reviewed by Bitanihirwe and Woo,
2011).
Patients with schizophrenia tend to exhibit an older appear-
ance than their biological age (Kirkpatrick et al., 2008). To date,
the most widely accepted hypothesis for this observation was
that the use of medication in combination with lifestyle factors
resulted in this aged phenotype, with consequently reduced lifes-
pans. Some groups have recently started to discuss whether inher-
ited biological processes that underlie schizophrenia could con-
tribute to the observed accelerate aging (Kirkpatrick et al., 2008;
Fernandez-Egea et al., 2009; Tang et al., 2009; Jeste et al., 2011).
Much biological evidence supports the theory that schizophrenia
shares common events related to age-related disorders, with spe-
cial consideration to the production of ROS.
During normal aging, oxidative stress levels increase while
GSH activity decreases (Finkel and Holbrook, 2000; Liu et al.,
2004; Currais and Maher, 2013). This is the first evidence
that strengthens the theory that schizophrenia could be a syn-
drome of accelerated aging in which GSH activity is altered
(Gysin et al., 2007). Moreover, reductions in telomere length,
another classical hallmark of aging, have been observed in
association with increased pulse pressures and a predisposi-
tion to diabetes in patients with schizophrenia, independent
of the influence of medication (Fernandez-Egea et al., 2009).
In terms of anatomical structures, some data has shown that
the aging in brains of patients with schizophrenia accelerate
faster than healthy subjects (Koutsouleris et al., 2014) with
reductions in the integrity of white matter (Mori et al., 2007;
Kochunov et al., 2013). In schizophrenia, oxidative damage can
be detected in plasma even during the first episode of psy-
chosis, where GSH has lower levels of activity (Micó et al.,
2011); this could provide a useful diagnostic biomarker of the
disease.
Additionally, changes in neuronal potential are often observed
in patients with schizophrenia, which appears to be a conse-
quence of oxidative stress (Ballesteros et al., 2013). This potential
disturbance results from a malfunction of the NMDA recep-
tors, another hallmark of schizophrenia. Disruption of NMDA
receptors could occur due to the over-oxidation of extracellular
sites of the receptor as a consequence of a deficiency in glu-
tathione production (Steullet et al., 2006). Imbalances in the
dopaminergic system are also frequently observed in schizophre-
nia, which may occur as a result of GSH alterations as reduced
levels of activity results in decreased dopamine levels (Jacob-
sen et al., 2005). As ROS are products of the degradation of
L-dopa and dopamine, the absence of GSH makes the sub-
stantia nigra vulnerable to toxic effects of ROS, with a con-
sequent reduction in the number of dopaminergic neurons.
Taken together, this data places ROS as a principle player in the
molecular and cellular pathophysiological mechanisms underly-
ing schizophrenia.
SUMMARY OF CRITICAL TARGETS FOR FURTHER
CONSIDERATION
In this review, we have summarized the numerous intersections
between redox state signaling and disease-associated aberrant
functions. Moreover, we have expanded our conceptual frame-
work to include non-neuronal and potentially peripheral sources
of ROS accumulation and aging cues in the development of
late-onset neuropathologies such as PD, AD, or schizophrenia.
Importantly, this review has emphasized those mechanisms that
are likely to be causal to cognitive impairments, in addition to the
roles of ROS in age-related neural damage. In Table 1, we have
provided a reference tool of what we believe to be the molecular
targets that can unravel the relationship between oxidative stress
and late-onset neurological disorders. In most cases, the findings
referenced below follow the development of detection protocols
that could be readily adapted to use for the high-throughput
screening of transformed neurons from iPSCs on the biological
backdrops of pathology and age acceleration. Correspondingly,
we predict great therapeutic gains from these loci in the years
ahead.
The development of age-accelerated procedures that can con-
vert stem cells into neurons may represent a powerful new
opportunity to quantify relationships between genetic predispo-
sition(s) or drug exposure(s) for any maturational or functional
redirection that results in an otherwise determined biological
system. Several strategies to accelerate aging have been explored in
this review, including the overexpression of prelamin A/progerin
to generate aged dopaminergic functional neurons, which were
successfully derived from reprogrammed PD fibroblasts by Miller
et al. The progerin disorders, however, overtly manifest symptoms
throughout the body, but do not affect nervous system function.
In order to explore alternative candidate pathways that might
produce new models, we examined the literature for cascades that
are altered by aging, which could propel the acceleration of aging
in neurons to study late-onset forms of neuronal dysfunction. We
have explored strategies based on studies related to brain aging
and sought insights based on studies from other systems, which
led us to suggest that adenosine and ROS may participate as
potential inductors of aging in vitro.
Senescence in general is frequently associated with redox
system deregulation, which directly impacts on ROS accumu-
lation and oxidative stress levels. The pathologies discussed in
this review are age-related and share common changes in ROS
levels that may result from alterations in different metabolic
pathways.
Going forward, an important goal in targeting and devel-
oping therapeutic interventions using neuronal microsystems of
aged neurons is the extent to which the locus of the disorder
is intrinsic vs. imposed upon the neuron. We encourage the
modeling of late-onset diseases using iPSCs, but some details may
need to be adjusted in order that such models could be used
to study the causes of these diseases and novel pharmacological
targets.
ACKNOWLEDGMENTS
We apologize if any of our colleagues involved in this study
were not cited due to space constraints or oversight. We thank
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 292 | 7
Campos et al. Accelerating neuronal development and disease
the National Council for Scientific and Technological Develop-
ment (CNPq), Brazilian Ministry of Health, Coordination for
the Improvement of Higher Education Personnel (CAPES) and
Carlos Chagas Filho Research Support Foundation of the State of
Rio de Janeiro (FAPERJ) who supported the authors. The authors
declare no conflicts of interest.
REFERENCES
Armstrong, L., Tilgner, K., Saretzki, G., Atkinson, S., Stojkovic, M., Moreno,
R., et al. (2010). Human induced pluripotent stem cell lines show stress
defense human embryonic stem cells. Stem Cells 28, 661–673. doi: 10.1002/
stem.307
Badger, J. L., Cordero-llana, O., Hartfield, E. M., and Wade-martins, R. (2014).
Parkinson’s disease in a dish—Using stem cells as a molecular tool. Neurophar-
macology 76, 88–96. doi: 10.1016/j.neuropharm.2013.08.035
Ballesteros, A., Summerfelt, A., Du, X., Jiang, P., Chiappelli, J., Tagamets, M.,
et al. (2013). Electrophysiological intermediate biomarkers for oxidative stress in
schizophrenia. Clin. Neurophysiol. 124, 2209–2215. doi: 10.1016/j.clinph.2013.
05.021
Barnham, K. J., Masters, C. L., and Bush, A. I. (2004). Neurodegenerative diseases
and oxidative stress. Nat. Rev. Drug Discov. 3, 205–214. doi: 10.1038/nrd1330
Bertram, L., and Tanzi, R. E. (2005). The genetic epidemiology of neurodegenera-
tive disease. J. Clin. Invest. 115, 1449–1457. doi: 10.1172/jci24761
Bezprozvanny, I., and Mattson, M. P. (2008). Neuronal calcium mishandling and
the pathogenesis of Alzheimer’s disease. Trends Neurosci. 31, 454–463. doi: 10.
1016/j.tins.2008.06.005
Bitanihirwe, B. K. Y., and Woo, T. W. (2011). Oxidative stress in schizophrenia:
an integrated approach. Neurosci. Biobehav. Rev. 35, 878–893. doi: 10.1016/j.
neubiorev.2010.10.008
Boison, D. (2008). Adenosine as a neuromodulator in neurological diseases. Curr.
Opin. Pharmacol. 8, 2–7. doi: 10.1016/j.coph.2007.09.002
Botella-López, A., Burgaya, F., Gavín, R., García-Ayllón, M. S., Gómez-Tortosa, E.,
Peña-Casanova, J., et al. (2006). Reelin expression and glycosylation patterns
are altered in Alzheimer’s disease. Proc. Natl. Acad. Sci. U S A 103, 5573–5578.
doi: 10.1073/pnas.0601279103
Byers, B., Cord, B., Nguyen, H. N., Schül, B., Fenno, L., Lee, P. C., et al. (2011).
SNCA triplication Parkinson’s patient’s iPSC-derived DA neurons accumulate
α-synuclein and are susceptible to oxidative stress. PLoS One 6:e26159. doi: 10.
1371/journal.pone.0026159
Calabrese, V., Guagliano, E., Sapienza, M., Panebianco, M., Calafato, S., Puleo,
E., et al. (2007). Redox regulation of cellular stress response in aging and
neurodegenerative disorders: role of vitagenes. Neurochem. Res. 32, 757–773.
doi: 10.1007/s11064-006-9203-y
Cannon, J. R., Tapias, V. M., Na, H. M., Honick, A. S., Drolet, R. E., and
Greenamyre, J. T. (2009). A high reproducoble rotenone model of Parkinson’s
disease. Neurobiol. Dis. 34, 279–290. doi: 10.1016/j.nbd.2009.01.016
Cardno, A. G., and Gottesman, I. I. (2000). Twin studies of schizophrenia: from
bow-and-arrow concordances to star wars Mx and functional genomics. Am.
J. Med. Genet. 97, 12–17. doi: 10.1002/(SICI)1096-8628(200021)97:1<12::AID-
AJMG3>3.0.CO;2-U
Castillo, C. A., Albasanz, J. L., León, D., Jordán, J., Pallàs, M., Camins, A.,
et al. (2009). Age-related expression of adenosine receptors in brain from the
senescence-accelerated mouse. Exp. Gerontol. 44, 453–461. doi: 10.1016/j.exger.
2009.04.006
Chaudhari, N., Talwar, P., Parimisetty, A., Lefebvre d’Hellencourt, C., and Ravanan,
P. (2014). A molecular web: endoplasmic reticulum stress, inflammation and
oxidative stress. Front. Cell. Neurosci. 8:213. doi: 10.3389/fncel.2014.00213
Circu, M. L., and Aw, T. Y. (2010). Reactive oxygen species, cellular redox systems
and apoptosis. Free Radic. Biol. Med. 48, 749–762. doi: 10.1016/j.freeradbiomed.
2009.12.022
Cooper, O., Seo, H., Andrabi, S., Guardia-Laguarta, C., Graziotto, J., Sundberg, M.,
et al. (2012). Pharmacological rescue of mitochondrial deficits in iPSC-derived
neural cells from patients with familial Parkinson’s disease. Sci. Transl. Med.
4:141ra90. doi: 10.1126/scitranslmed.3003985
Currais, A., and Maher, P. (2013). Functional consequences of age-dependent
changes in glutathione status in the brain. Antioxid. Redox Signal. 19, 813–822.
doi: 10.1089/ars.2012.4996
Dias, V., Junn, E., and Mouradian, M. M. (2013). The role of oxidative stress in
Parkinson’s disease. J. Parkinsons. Dis. 3, 461–491. doi: 10.3233/JPD-130230
Dror, N., Klein, E., Karry, R., Sheinkman, A., Kirsh, Z., Mazor, M., et al. (2002).
State-dependent alterations in mitochondrial complex I activity in platelets:
a potential peripheral marker for schizophrenia. Mol. Psychiatry 7, 995–1001.
doi: 10.1038/sj.mp.4001116
Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F., and Loguercio, C. (2007).
Chronic inflammation and oxidative stress in human carcinogenesis. Int. J.
Cancer 121, 2381–2386. doi: 10.1002/ijc.23192
Fernandez-Egea, E., Bernardo, M., Heaphy, C. M., Griffith, J. K., Parellada, E.,
Esmatjes, E., et al. (2009). Telomere length and pulse pressure in newly diag-
nosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr. Bull.
35, 437–442. doi: 10.1093/schbul/sbn169
Finkel, T., and Holbrook, N. J. (2000). Oxidants, oxidative stress and the biology of
ageing. Nature 408, 239–247. doi: 10.1038/35041687
Ghneim, H. K., Al-Saleh, S. S., Al-Shammary, F. J., and Kordee, Z. S. (2003).
Changes in adenosine deaminase activity in ageing cultured human cells and
the role of zinc. Cell Biochem. Funct. 21, 275–282. doi: 10.1002/cbf.1023
Gysin, R., Kraftsik, R., Sandell, J., Bovet, P., Chappuis, C., Conus, P., et al.
(2007). Impaired glutathione synthesis in schizophrenia: convergent genetic and
functional evidence. Proc. Natl. Acad. Sci. U S A 104, 16621–16626. doi: 10.
1073/pnas.0706778104
Herz, J., and Chen, Y. (2006). Reelin, lipoprotein receptors and synaptic plasticity.
Nat. Rev. Neurosci. 7, 850–859. doi: 10.1038/nrn2009
Hooper, C., Killick, R., and Lovestone, S. (2008). The GSK3 hypothesis of
Alzheimer’s disease. J. Neurochem. 104, 1433–1439. doi: 10.1111/j.1471-4159.
2007.05194.x
Hsieh, H.-L., and Yang, C.-M. (2013). Role of redox signaling in neuroinflam-
mation and neurodegenerative diseases. Biomed Res. Int. 2013:484613. doi: 10.
1155/2013/484613
Hu, B.-Y., and Zhang, S.-C. (2009). Differentiation of spinal motor neurons from
pluripotent human stem cells. Nat. Protoc. 4, 1295–1304. doi: 10.1038/nprot.
2009.127
Insel, T. R. (2010). Rethinking schizophrenia. Nature 468, 187–193. doi: 10.
1038/nature09552
Jacobsen, J. P. R., Rodriguiz, R. M., Mørk, A., and Wetsel, W. C. (2005).
Monoaminergic dysregulation in glutathione-deficient mice: possible relevance
to schizophrenia? Neuroscience 132, 1055–1072. doi: 10.1016/j.neuroscience.
2005.01.059
Jeste, D. V., Wolkowitz, O. M., and Palmer, B. W. (2011). Divergent trajectories of
physical, cognitive and psychosocial aging in schizophrenia. Schizophr. Bull. 37,
451–455. doi: 10.1093/schbul/sbr026
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., and Selkoe, D. J. (2011).
Soluble amyloid β -protein dimers isolated from Alzheimer cortex directly
induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad.
Sci. U S A 108, 5819–5824. doi: 10.1073/pnas.1017033108
Jung, H.-J., Coffinier, C., Choe, Y., Beigneux, A. P., Davies, B. S. J., Yang, S. H., et al.
(2012). Regulation of prelamin A but not lamin C by miR-9, a brain-specific
microRNA. Proc. Natl. Acad. Sci. U S A 109, E423–E431. doi: 10.1073/pnas.
1111780109
Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S.,
Wojtkiewicz, G. R., et al. (2014). Vascular and neurogenic rejuvenation of the
aging mouse brain by young systemic factors. Science 344, 630–634. doi: 10.
1126/science.1251141
Keeney, P. M., Xie, J., Capaldi, R. A., and Bennett, J. P. Jr. (2006). Parkinson’s
disease brain mitochondrial complex I has oxidatively damaged subunits and
is functionally impaired and misassembled. J. Neurosci. 26, 5256–5264. doi: 10.
1523/jneurosci.0984-06.2006
Kelly, R. D. W., Sumer, H., McKenzie, M., Facucho-oliveira, J., Trounce, I. A.,
Verma, P. J., et al. (2013). The effects of nuclear reprogramming on mito-
chondrial DNA replication. Stem Cell Rev. 9, 1–15. doi: 10.1007/s12015-011-
9318-7
Kirkpatrick, B., Messias, E., Harvey, P. D., Fernandez-Egea, E., and Bowie, C. R.
(2008). Is schizophrenia a syndrome of accelerated aging? Schizophr. Bull. 34,
1024–1032. doi: 10.1093/schbul/sbm140
Kochunov, P., Glahn, D. C., Rowland, L. M., Olvera, R. L., Winkler, A., Yang, Y.,
et al. (2013). Testing the hypothesis of accelerated cerebral white matter aging
in schizophrenia and major depression. Biol. Psychiatry 73, 482–491. doi: 10.
1016/j.biopsych.2012.10.002
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 292 | 8
Campos et al. Accelerating neuronal development and disease
Koutsouleris, N., Davatzikos, C., Borgwardt, S., Gaser, C., Bottlender, R., Frodl,
T., et al. (2014). Accelerated brain aging in schizophrenia and beyond: a
neuroanatomical marker of psychiatric disorders. Schizophr. Bull. 40, 1140–
1153. doi: 10.1093/schbul/sbt142
Kulak, A., Steullet, P., Cabungcal, J.-H., Werge, T., Ingason, A., Cuenod, M.,
et al. (2013). Redox dysregulation in the pathophysiology of schizophrenia and
bipolar disorder: insights from animal models. Antioxid. Redox Signal. 18, 1428–
1443. doi: 10.1089/ars.2012.4858
Le Belle, J. E., Orozco, N. M., Paucar, A. A., Saxe, J. P., Mottahedeh, J., Pyle, A. D.,
et al. (2011). Proliferative neural stem cells have high endogenous ROS levels
that regulate self-renewal and neurogenesis in a PI3K/Akt-dependant manner.
Cell Stem Cell 8, 59–71. doi: 10.1016/j.stem.2010.11.028
Liochev, S. I. (2013). Reactive oxygen species and the free radical theory of aging.
Free Radic. Biol. Med. 60, 1–4. doi: 10.1016/j.freeradbiomed.2013.02.011
Liu, A. Y., Chang, Z. F., and Chen, K. Y. (1986). Increased level of cAMP-dependent
protein kinase in aging human lung fibroblasts. J. Cell. Physiol. 128, 149–154.
doi: 10.1002/jcp.1041280203
Liu, H., Wang, H., Shenvi, S., Hagen, T. M., and Liu, R.-M. (2004). Glutathione
metabolism during aging and in Alzheimer disease. Ann. N Y Acad. Sci. 1019,
346–349. doi: 10.1196/annals.1297.059
Liu, B., and Zhou, Z. (2008). Lamin A/C, laminopathies and premature ageing.
Histol. Histopathol. 23, 747–763.
Mackiewicz, M., Nikonova, E. V., Zimmermann, J. E., Romer, M. A., Cater, J.,
Galante, R. J., et al. (2006). Age-related changes in adenosine metabolic enzymes
in sleep/wake regulatory areas of the brain. Neurobiol. Aging 27, 351–360.
doi: 10.1016/j.neurobiolaging.2005.01.015
Mariani, J., Vittoria, M. V., Palejev, D., Tomasini, L., Coppola, G., Szekely, A. M.,
et al. (2012). Modeling human cortical development in vitro using induced
pluripotent stem cells. Proc. Natl. Acad. Sci. U S A 109, 12770–12775. doi: 10.
1073/pnas.1202944109
Marion, R. M., Strati, K., Li, H., Tejera, A., Schoeftner, S., Ortega, S., et al. (2009).
Telomeres acquire embryonic stem cell characteristics in induced pluripotent
stem cells. Cell Stem Cell 4, 141–154. doi: 10.1016/j.stem.2008.12.010
Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D.,
et al. (2007). Mitochondrial oxidative stress causes hyperphosphorylation of tau.
PLoS One 2:e536. doi: 10.1371/journal.pone.0000536
Micó, J. A., Rojas-Corrales, M. O., Gibert-Rahola, J., Parellada, M., Moreno,
D., Fraguas, D., et al. (2011). Reduced antioxidant defense in early onset
first-episode psychosis: a case-control study. BMC Psychiatry 11:26. doi: 10.
1186/1471-244X-11-26
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., et al.
(2013). Human iPSC-based modeling of late-onset disease via progerin-induced
aging. Cell Stem Cell 13, 691–705. doi: 10.1016/j.stem.2013.11.006
Miyoshi, N., Oubrahim, H., Chock, P. B., and Stadtman, E. R. (2006). Age-
dependent cell death and the role of ATP in hydrogen peroxide-induced apopto-
sis and necrosis. Proc. Natl. Acad. Sci. U S A 103, 1727–1731. doi: 10.1073/pnas.
0510346103
Molofsky, A. V., Slutsky, S. G., Joseph, N. M., He, S., Pardal, R., Krishnamurthy, J.,
et al. (2006). Increasing p16INK4a expression decreases forebrain progenitors
and neurogenesis during ageing.Nature 443, 448–452. doi: 10.1038/nature05091
Mori, T., Ohnishi, T., Hashimoto, R., Nemoto, K., Moriguchi, Y., Noguchi, H.,
et al. (2007). Progressive changes of white matter integrity in schizophrenia
revealed by diffusion tensor imaging. Psychiatry Res. 154, 133–145. doi: 10.
1016/j.pscychresns.2006.09.004
Murakami, K., Murata, N., Noda, Y., Tahara, S., Kaneko, T., Kinoshita, N., et al.
(2011). SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid β
protein oligomerization and memory loss in mouse model of Alzheimer disease.
J. Biol. Chem. 286, 44557–44568. doi: 10.1074/jbc.M111.279208
Murray, R. M., and Lewis, S. W. (1987). Is schizophrenia a neurodevelopmental
disorder? Br. Med. J. 295, 681–682. doi: 10.1136/bmj.295.6608.1278-c
Nayernia, Z., Jaquet, V., and Krause, K.-H. (2014). New insights on NOX enzymes
in the central nervous system. Antioxid. Redox Signal. 20, 2815–2837. doi: 10.
1089/ars.2013.5703
Nguyen, H. N., Byers, B., Cord, B., Shcheglovitov, A., Byrne, J., Gujar, P., et al.
(2011). LRRK2 mutant iPSC-derived DA neurons demonstrate increased sus-
ceptibility to oxidative stress.Cell StemCell 8, 267–280. doi: 10.1016/j.stem.2011.
01.013
Nicholas, C. R., Chen, J., Tang, Y., Southwell, D. G., Vogt, D., Arnold, C. M., et al.
(2014). Functional maturation of hPSC-derived forebrain interneurons requires
an extended timeline and mimics human neural development. Cell Stem Cell 12,
573–586. doi: 10.1016/j.stem.2013.04.005
Nissan, X., Blondel, S., Navarro, C., Maury, Y., Denis, C., Girard, M., et al. (2012).
Unique preservation of neural cells in Hutchinson- Gilford progeria syndrome
is due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2, 1–9.
doi: 10.1016/j.celrep.2012.05.015
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E., et al. (2001).
Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp.
Neurol. 60, 759–767.
Parish, S. T., Kim, S., Sekhon, R. K., Wu, J. E., and Kawakatsu, Y. (2013). Adenosine
deaminase modulation of telomerase activity and replicative senescence in
human CD8 lymphocytes. J. Immunol. 184, 2847–2854. doi: 10.4049/jimmunol.
0903647
Paulsen, B. D. S., de Moraes Maciel, R., Galina, A., Souza da Silveira, M., dos
Santos Souza, C., Drummond, H., et al. (2012). Altered oxygen metabolism
associated to neurogenesis of induced pluripotent stem cells derived from a
schizophrenic patient. Cell Transplant. 21, 1547–1559. doi: 10.3727/096368911X
600957
Popa-Wagner, A., Mitran, S., Sivanesan, S., Chang, E., and Buga, A.-M. (2013).
ROS and brain diseases: the good, the bad and the ugly. Oxid. Med. Cell. Longev.
2013:963520. doi: 10.1155/2013/963520
Rafalski, V. A., and Brunet, A. (2011). Energy metabolism in adult neural stem cell
fate. Prog. Neurobiol. 93, 182–203. doi: 10.1016/j.pneurobio.2010.10.007
Ragnauth, C. D., Warren, D. T., Liu, Y., McNair, R., Tajsic, T., Figg, N., et al.
(2010). Prelamin A acts to accelerate smooth muscle cell senescence and is a
novel biomarker of human vascular aging. Circulation 121, 2200–2210. doi: 10.
1161/CIRCULATIONAHA.109.902056
Rodier, F., and Campisi, J. (2011). Four faces of cellular senescence. J. Cell Biol. 192,
547–556. doi: 10.1083/jcb.201009094
Ryder, J., Su, Y., and Ni, B. (2004). Akt/GSK3β serine/threonine kinases: evidence
for a signalling pathway mediated by familial Alzheimer’s disease mutations.
Cell. Signal. 16, 187–200. doi: 10.1016/j.cellsig.2003.07.004
Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., and Jazin, E.
(2007). Inflammation-related genes up-regulated in schizophrenia brains. BMC
Psychiatry 7:46. doi: 10.1186/1471-244X-7-46
Saha, K., and Jaenisch, R. (2009). Technical challenges in using human induced
pluripotent stem cells to model disease. Cell Stem Cell 5, 584–595. doi: 10.1016/j.
stem.2009.11.009
Shetty, A. K., Hattiangady, B., and Shetty, G. A. (2005). Stem/progenitor cell
proliferation factors FGF-2, IGF-1 and VEGF exhibit early decline during the
course of aging in the hippocampus: role of astrocytes. Glia 51, 173–186. doi: 10.
1002/glia.20187
Smith, E. D., Kudlow, B. A., Frock, R. L., and Kennedy, B. K. (2005). A-type nuclear
lamins, progerias and other degenerative disorders. Mech. Ageing Dev. 126, 447–
460. doi: 10.1016/j.mad.2004.10.006
Steullet, P., Neijt, H. C., Cuénod, M., and Do, K. Q. (2006). Synaptic plasticity
impairment and hypofunction of NMDA receptors induced by glutathione
deficit: relevance to schizophrenia. Neuroscience 137, 807–819. doi: 10.1016/j.
neuroscience.2005.10.014
Stoll, E. A., Cheung, W., Mikheev, A. M., Sweet, I. R., Bielas, J. H., Zhang, J., et al.
(2011). Aging neural progenitor cells have decreased mitochondrial content and
lower oxidative metabolism. J. Biol. Chem. 286, 38592–38601. doi: 10.1074/jbc.
M111.252171
Suhr, S. T., Chang, E. A., Tjong, J., Alcasid, N., Perkins, G. A., Goissis, M. D.,
et al. (2010). Mitochondrial rejuvenation after induced pluripotency. PLoS One
5:e14095. doi: 10.1371/journal.pone.0014095
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663–
676. doi: 10.1016/j.cell.2006.07.024
Tang, B., Chang, W., Lanigan, C. M., Dean, B., Sutcliffe, J. G., and Thomas,
E. A. (2009). Normal human aging and early-stage schizophrenia share com-
mom molecular profiles. Aging Cell 8, 339–342. doi: 10.1111/j.1474-9726.2009.
00468.x
Uttara, B., Singh, A. V., Zamboni, P., and Mahajan, R. T. (2009). Oxidative
stress and neurodegenerative diseases: a review of upstream and downstream
antioxidant therapeutic options. Curr. Neuropharmacol. 7, 65–74. doi: 10.
2174/157015909787602823
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I.,
Luo, J., et al. (2014). Young blood reverses age-related impairments in cognitive
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 292 | 9
Campos et al. Accelerating neuronal development and disease
function and synaptic plasticity in mice. Nat. Med. 20, 1–8. doi: 10.1038/nm.
3569
Viteri, G., Chung, Y. W., and Stadtman, E. R. (2010). Effect of progerin on
the accumulation of oxidized proteins in fibroblasts from Hutchinson Gilford
progeria patients. Mech. Ageing Dev. 131, 2–8. doi: 10.1016/j.mad.2009.11.006
Wyss-Coray, T. (2006). Inflammation in Alzheimer disease: driving force, bystander
or beneficial response? Nat. Med. 12, 1005–1015. doi: 10.1038/nm1484
Yan, Y., Yang, D., Zarnowska, E. D., Du, Z., Werbel, B., Valliere, C., et al. (2005).
Directed differentiation of dopaminergic neuronal subtypes from human
embryonic stem cells. Stem Cells 23, 781–790. doi: 10.1634/stemcells.2004-0365
Yang, Y., Bazhin, A. V., Werner, J., and Karakhanova, S. (2013a). Reactive oxy-
gen species in the immune system. Int. Rev. Immunol. 32, 249–270. doi: 10.
3109/08830185.2012.755176
Yang, D., Song, J., Wu, L., Ma, Y., Song, C., Dovat, S., et al. (2013b). Induction of
senescence by adenosine suppressing the growth of lung cancer cells. Biochem.
Biophys. Res. Commun. 440, 62–67. doi: 10.1016/j.bbrc.2013.09.030
Yin, F., Jiang, T., and Cadenas, E. (2013). Metabolic triad in brain aging: mitochon-
dria, insulin/IGF-1 signalling and JNK signalling. Biochem. Soc. Trans. 41, 101–
105. doi: 10.1042/BST20120260
Yoshikawa, K. (2000). Cell cycle regulators in neural stem cells and postmitotic
neurons. Neurosci. Res. 37, 1–14. doi: 10.1016/S0168-0102(00)00101-2
Zhang, Y., Pak, C., Han, Y., Ahlenius, H., Zhang, Z., Chanda, S., et al.
(2013). Rapid single-step induction of functional neurons from human
pluripotent stem cells. Neuron 78, 785–798. doi: 10.1016/j.neuron.2013.
05.029
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 17 July 2014; accepted: 06 October 2014; published online: 27 October 2014.
Citation: Campos PB, Paulsen BS and Rehen SK (2014) Accelerating neuronal aging
in in vitro model brain disorders: a focus on reactive oxygen species. Front. Aging
Neurosci. 6:292. doi: 10.3389/fnagi.2014.00292
This article was submitted to the journal Frontiers in Aging Neuroscience.
Copyright © 2014 Campos, Paulsen and Rehen. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution and reproduction in other forums is permitted, pro-
vided the original author(s) or licensor are credited and that the original publi-
cation in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 292 | 10
